Analysts Are Bullish on These Healthcare Stocks: ALBO, ZYNE

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Albireo Pharma Inc (NASDAQ: ALBO) and Zynerba Pharmaceuticals (NASDAQ: ZYNE) with bullish sentiments.

Albireo Pharma Inc (NASDAQ: ALBO)

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Albireo Pharma Inc (NASDAQ: ALBO), with a price target of $58. The company’s shares opened today at $27.29, close to its 52-week high of $29.20.

According to TipRanks.com, Moussatos is a 5-star analyst with an average return of 11.2% and a 46.9% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as KalVista Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.

Albireo Pharma Inc has an analyst consensus of Strong Buy, with a price target consensus of $61.67.

Zynerba Pharmaceuticals (NASDAQ: ZYNE)

In a report released today, Elemer Piros from Cantor Fitzgerald reiterated a Buy rating on Zynerba Pharmaceuticals (NASDAQ: ZYNE), with a price target of $17. The company’s shares opened today at $13.46.

Piros said:

“Zynerba updated its plans to focus development on rare and near-rare neurological and psychiatric disorders.”

According to TipRanks.com, Piros is ranked 0 out of 5 stars with an average return of -9.9% and a 42.4% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Dimension Therapeutics Inc.

Zynerba Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $17.25.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.